April 23, 2025 a 08:31 am
CRL: Analysts Ratings - Charles River Laboratories International, Inc.
Over the past several months, Charles River Laboratories International, Inc., identified with the ticker CRL, has displayed a dynamic shift in analyst sentiment. The weighted inclination towards a more cautious investment stance is evident. With its broad scope in the non-clinical contract research sector, the company continues to attract significant attention and mixed reviews from analysts. This environment of fluctuating investor confidence demonstrates both challenges and opportunities for CRL.
Historical Stock Grades
The table below captures the analyst ratings as of April 2025, offering insights into the prevailing sentiment towards CRL stock.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 2 | |
| Hold | 16 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over the months, a marked shift has been observed in the analyst sentiment regarding CRL. - The number of 'Strong Buy' recommendations has gradually decreased from September 2022. - A steady increase in 'Hold' ratings is evident, suggesting a more cautious approach by analysts. - The total number of ratings has remained fairly constant with a slight inclination towards neutral positions.
Percentage Trends
The percentage allocation of analyst ratings over time reflects discernible trends. - There is a noticeable reduction in 'Strong Buy' percentages, while 'Hold' percentages surged significantly. - Adjustments in 'Sell' and 'Strong Sell' have remained minimal. - Past months highlight a growing neutrality and skepticism towards aggressive buying. - The last half-year has seen heightened caution, with an emphasis on holding positions rather than buying.
Latest Analyst Recommendations
Recent analyst recommendations provide further insights:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-10 | Equal Weight | Equal Weight | Barclays |
| 2025-04-09 | Neutral | Neutral | Mizuho |
| 2025-03-21 | Neutral | Buy | Goldman Sachs |
| 2025-03-04 | Neutral | Sell | Citigroup |
| 2025-02-20 | Equal Weight | Equal Weight | Barclays |
Analyst Recommendations with Change of Opinion
The following table summarizes the recommendations with significant changes:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-03-21 | Neutral | Buy | Goldman Sachs |
| 2025-03-04 | Neutral | Sell | Citigroup |
| 2025-01-22 | Market Perform | Outperform | William Blair |
| 2025-01-17 | Neutral | Buy | UBS |
| 2024-10-07 | In Line | Outperform | Evercore ISI Group |
Interpretation
The analyst sentiment towards Charles River Laboratories International, Inc. reveals a notable shift towards caution, as evidenced by increased 'Hold' ratings and neutral recommendations. This suggests a growing uncertainty among analysts regarding the company's future performance. The consistency in maintaining neutral stances signifies a stabilizing period, yet it hints at underlying concerns about the sector's current dynamics and future prospects.
Conclusion
In summary, while Charles River Laboratories International, Inc. operates in a robust and expansive market, the increase in neutral and hold recommendations suggests a cautious approach among analysts. Though the company's diversified operations offer growth opportunities, the prevailing sentiment indicates uncertainty about short-term performance. As analysts continue to reassess their positions, investors should carefully weigh these ratings, acknowledging both the inherent opportunities and risks.